Vandetanib Shows Clinical Benefit When Combined With Docetaxel For Lung Cancer
Tuesday, June 2, 2009 - 21:21
in Health & Medicine
When combined with standard chemotherapy, an international Phase III trial has shown that the oral targeted therapy vandetanib improves progression-free survival for patients with advanced non-small cell lung cancer, according to research.
Read the whole article on Science Daily
More from Science Daily
Related
- Vandetanib shows clinical benefit when combined with docetaxel for lung cancerMon, 1 Jun 2009, 9:44:28 EDT
- Study shows drug combination improves outcome for advanced non-small cell lung cancerSat, 30 May 2009, 11:29:37 EDT
- Chemotherapy plus targeted therapies shows improved survival in advance-stage lung cancer patientsThu, 13 Nov 2008, 10:51:01 EST
- Advanced lung cancer patients see improved, progression-free survivalThu, 13 Nov 2008, 10:51:04 EST
- New treatment combination proves safe, effective for head and neck cancer patientsMon, 2 Jun 2008, 17:14:58 EDT